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Abstract 
 
The extracellular calcium (Ca
2+
o)-sensing receptor (CaSR) is a family C G-protein-coupled receptor, 
which detects alterations in Ca2+o concentrations, and modulates parathyroid hormone secretion and 
urinary calcium excretion. The central role of the CaSR in Ca2+o homeostasis has been highlighted by 
the identification of mutations affecting the CASR gene on chromosome 3q21.1. Loss-of-function 
CASR mutations cause familial hypocalciuric hypercalcaemia (FHH), whilst gain-of-function 
mutations lead to autosomal dominant hypocalcaemia (ADH). However, CASR mutations are only 
detected in ≤70% of FHH and ADH cases, referred to as FHH type 1 and ADH type 1, respectively, 
and studies in other FHH and ADH kindreds have revealed these disorders to be genetically 
heterogeneous. Thus, loss- and gain-of-function mutations of the GNA11 gene on chromosome 
19p13.3, which encodes the G-protein-α11 (Gα11) subunit, lead to FHH type 2 and ADH type 2, 
respectively; whilst loss-of-function mutations of AP2S1 on chromosome 19q13.3, which encodes the 
adaptor-related protein complex 2 sigma (AP2σ) subunit, cause FHH type 3. These studies have 
demonstrated Gα11 to be a key mediator of downstream CaSR signal transduction, and also revealed a 
role for AP2σ, which is involved in clathrin-mediated endocytosis, in CaSR signaling and trafficking. 
Moreover, FHH type 3 has been demonstrated to represent a more severe FHH variant that may lead 
to symptomatic hypercalcaemia, low bone mineral density and cognitive dysfunction. In addition, 
calcimimetic and calcilytic drugs, which are positive and negative CaSR allosteric modulators, 
respectively, have been shown to be of potential benefit for these FHH and ADH disorders. 
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Introduction 
 
Extracellular calcium (Ca
2+
o) is essential for the regulation of a variety of biological processes that 
include neuromuscular excitability, blood coagulation, mineralisation of bone matrix, and also for 
providing a steady supply of calcium for intracellular functions ranging from muscle contraction to 
hormone synthesis and secretion (Brown 1991). Thus, there is a requirement for Ca
2+
o to be tightly 
regulated, and a complex homeostatic system has evolved to maintain Ca2+o at near constant 
concentrations (Fig. 1) (Thakker 2016). The Ca2+o homeostatic system comprises four main 
components: 1) the parathyroid glands, which sense the prevailing Ca
2+
o concentrations and regulate 
the actions of target calcitropic organs; 2) the intestine and kidneys, which facilitate the transfer of 
calcium between the external environment and extracellular fluid; 3) the skeleton, which represents 
the major reservoir of total body calcium and is critical for buffering short-term changes in Ca
2+
o 
concentrations; and 4) calcitropic hormones such as parathyroid hormone (PTH) and 1,25-
dihydroxyvitamin D3, which mediate the interactions between the parathyroid glands, bone, kidney 
and intestines (Fig. 1). Thus, low Ca2+o concentrations lead to PTH release from the parathyroid 
glands, and this hormone exerts three distinct effects on Ca2+o homeostasis, which are to enhance: 
bone resorption, urinary calcium
 
reabsorption, and the renal synthesis of 1,25-dihydroxyvitamin D3, 
thereby leading to intestinal calcium absorption (Fig. 1). Low Ca2+o concentrations are also sensed by 
the kidneys, which increase urinary calcium reabsorption independently of the actions of PTH (Loupy, 
et al. 2012; Riccardi and Valenti 2016). These combined events mediate a rise in Ca
2+
o concentrations, 
which together with 1,25-dihydroxyvitamin D3, leads to feedback inhibition of PTH secretion (Fig. 1) 
(Thakker 2016). 
Studies of patients and kindreds with familial hypocalciuric hypercalcaemia (FHH) or 
autosomal dominant hypocalcaemia (ADH) have helped to elucidate the molecular basis of Ca2+o 
sensing and overall regulation of Ca2+o
 homeostasis by calcitropic tissues such as the parathyroid 
glands and kidneys, and revealed the involvement of a G-protein-coupled receptor (GPCR) pathway 
that comprises the calcium-sensing receptor (CaSR), G-protein-α11 (Gα11) subunit, and adaptor-
related protein complex 2 sigma (AP2σ) subunit (Nesbit, et al. 2013a; Nesbit, et al. 2013b; Pollak, et 
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al. 1993). This article will provide an overview of the role of the CaSR, Gα11 and AP2σ proteins, 
review the disorders caused by mutations of these proteins, outline potential targeted therapies, and 
describe insights gained into the molecular basis of Ca
2+
o
 
homeostasis by studies of the CaSR and its 
partner proteins. 
 
Overview of calcium-sensing receptor signalling and trafficking 
 
The human CaSR is a 1078 amino acid dimeric cell-surface protein that belongs to class C of the 
GPCR superfamily, which also includes the metabotropic glutamate, gamma-aminobutyric acid type 
B (GABAB), and taste 1 receptors (Katritch, et al. 2013). The CaSR is highly expressed in the 
parathyroid glands and kidneys (Regard, et al. 2008), and has a large (612 amino acid) extracellular 
domain (ECD), which has recently been crystallised and shown to comprise two globular lobes that 
adopt a venus flytrap (VFT) conformation (Zhang, et al. 2016). The cleft region located between the 
two lobes of the VFT is predicted to bind Ca
2+
o (Fig. 2) (Hannan, et al. 2012; Huang, et al. 2007), 
thereby leading to the activation of multiple intracellular signalling cascades via interactions with its 
transmembrane and intracellular domains (Conigrave and Ward 2013; Hofer and Brown 2003). In the 
parathyroid glands, the Gq/11 family of heterotrimeric guanine nucleotide-binding proteins (G-proteins) 
are considered to represent the major downstream signalling partners for the CaSR (Nesbit et al. 
2013a; Varrault, et al. 1995; Wettschureck, et al. 2007). The binding of the CaSR to the Gq and G11 
proteins is predicted to lead to dissociation of the respective Gα-subunits from their obligate Gβγ 
heterodimer, which activate the phospholipase C-beta (PLCβ) enzyme, thereby facilitating the 
hydrolysis of a plasma membrane lipid constituent, known as phosphatidylinositol 4,5-bisphosphate 
(PIP2), to produce inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Fig. 2) (Conigrave and 
Ward 2013; Hofer and Brown 2003). IP3 in turn stimulates the rapid release of Ca
2+ from intracellular 
stores (Breitwieser and Gama 2001), whilst DAG activates the mitogen-activated protein kinase 
(MAPK) cascade (Corbetta, et al. 2002), and these intracellular events mediate a decrease in PTH 
secretion from the parathyroid chief cell and a reduction in renal tubular calcium reabsorption (Fig. 
2). The level of CaSR cell-surface expression likely influences Ca
2+
o homeostasis, and is regulated by 
Page 4 of 37
jme@bioscientifica.com
Manuscript submitted for review to Journal of Molecular Endocrinology
For Review Only
 5
agonist-driven insertional signaling (ADIS), which leads to enhanced anterograde trafficking of newly 
synthesised receptors to the plasma membrane following prolonged exposure to Ca2+o (Grant, et al. 
2011). Moreover, the β-arrestin protein together with the adaptor-related protein complex 2 (AP2), 
which comprises a heterotetrameric complex of α-, β-,µ- and σ-subunits (Nesbit et al. 2013b) is 
considered to facilitate CaSR internalisation from the plasma membrane by clathrin-mediated 
endocytosis and retrograde trafficking (Breitwieser 2013). Thus, AP2 and β-arrestin likely represent 
key determinants of CaSR cell-surface expression. 
 
Disorders associated with calcium-sensing receptor mutations 
 
More than 230 different germline mutations of the CaSR, which is encoded by the CASR gene (Fig. 3) 
located on chromosome 3q21.1, have been reported (Hannan and Thakker 2013). These mutations 
may cause: a loss of CaSR function and give rise to hypercalcaemic disorders such as FHH type 1 
(FHH1), neonatal severe hyperparathyroidism (NSHPT), and adult-onset primary 
hyperparathyroidism (PHPT); or lead to a gain-of-function that is associated with hypocalcaemic 
disorders such as ADH type 1 (ADH1) and Bartter syndrome type V (Table 1) (Hannan and Thakker 
2013). 
 
Familial hypocalciuric hypercalcaemia type 1 (FHH1) 
FHH comprises three genetically distinct conditions, designated as FHH types 1-3 (Table 1), which 
are due to loss-of-function mutations affecting the CaSR, Gα11, and AP2σ proteins, respectively 
(Nesbit et al. 2013a; Nesbit et al. 2013b; Pollak et al. 1993). FHH1 (OMIM #145980) is the most 
common type and accounts for ~65% of all FHH cases (Hannan et al. 2012). FHH is a highly 
penetrant autosomal dominant condition characterised by lifelong non-progressive mild-to-moderate 
hypercalcaemia, normal (in ~80% of patients) or mildly raised serum PTH levels (in ~20% of 
patients) (Firek, et al. 1991), and low urinary calcium excretion (in ~95% of patients) (Marx 2015). 
FHH is considered to be a benign disorder, as patients are typically asymptomatic (Hannan and 
Thakker 2013). However, an increased prevalence of chondrocalcinosis with advancing age (Volpe, et 
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al. 2009) and occasional cases of pancreatitis have been reported (Pearce, et al. 1996c), and 
individuals with FHH have been misdiagnosed as having PHPT and undergone parathyroidectomy, 
which generally fails to normalize the hypercalcaemia (Hannan and Thakker 2013). Mutational 
analysis may be required to distinguish FHH from PHPT, and to-date FHH1 has been associated with 
>130 different mutations of the CASR gene (Fig. 3), which are missense substitutions in >85% of 
cases, whilst nonsense, deletion, insertion and splice-site mutations that lead to truncated CaSR 
proteins have been described in <15% of cases (Hannan et al. 2012; Hannan and Thakker 2013). 
Studies of FHH1-associated CaSR mutations have identified critical receptor structure-function 
relationships and demonstrated a mutational hotspot within the ECD. Indeed, an analysis of the 
locations of recurrent FHH1-causing CaSR mutations or residues affected by multiple different loss-
of-function CaSR mutations have revealed a clustering of mutations at the major predicted Ca
2+
o 
binding site located within the cleft region of the bilobed extracellular VFT domain of the CaSR (Fig. 
3) (Hannan et al. 2012). These mutated residues may be directly involved in the binding of Ca2+o or 
indirectly influence alterations in receptor conformational states that occur upon Ca
2+
o binding 
(Hannan et al. 2012; Huang, et al. 2009; Huang et al. 2007). Moreover, in vitro functional expression 
studies have identified specific VFT domain residues, which when mutated, can result in opposing 
effects on CaSR responses and lead to a loss- or gain-of-function (Fig. 3) (Hannan et al. 2012; Zhang, 
et al. 2014). These residues may potentially act as intra-molecular switches to regulate the entry and 
binding of Ca2+o within the VFT cleft region (Fig. 3) (Hannan et al. 2012; Zhang et al. 2014). FHH-
causing mutations also cluster in the CaSR transmembrane domain (TMD) and may inhibit the 
transmission of activation signals to the intracellular environment, by impairing interactions with 
heterotrimeric G-proteins and other components of the CaSR signal transduction pathway (Leach, et 
al. 2012). Some loss-of-function CaSR mutations have been shown to cause signalling bias by 
switching the wild-type CaSR from preferentially coupling with intracellular Ca2+ (Ca
2+
i) to a mutant 
receptor that signals equally via the Ca2+i and MAPK pathways, or which predominantly acts via 
MAPK (Leach et al. 2012). Loss-of-function CaSR mutations causing signalling bias are located 
within the ECD and TMD; however, the structural motifs within these regions that determine whether 
the CaSR preferentially couples to Ca
2+
i or MAPK pathways remain to be established. Around 50% of 
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CaSR mutations that lead to FHH1 have been shown to result in reduced cell-surface receptor 
expression as a consequence of defective trafficking to the plasma membrane, with mutant CaSRs 
being retained intracellularly and unable to exit either the endoplasmic reticulum or Golgi apparatus 
(Huang and Breitwieser 2007; White, et al. 2009). Such cellular studies also provide an explanation 
for the benign phenotype of FHH1, which is a heterozygous condition, as they have demonstrated that 
co-expression of wild-type and mutant FHH1-causing CaSRs ameliorates the loss-of-function, with 
the co-expressed wild-type CaSRs increasing trafficking of mutant receptors to the plasma membrane 
via the ADIS mechanism (Grant, et al. 2012). Whereas, cells expressing only mutant loss-of-function 
CaSRs have both defective membrane targeting and reduced signalling responses (Grant et al. 2012). 
 
Neonatal severe hyperparathyroidism (NSHPT)  
NSHPT (OMIM #239200) is a potentially life-threatening disorder most often caused by homozygous 
or compound heterozygous loss-of-function CaSR mutations (Table 1) (Chattopadhyay and Brown 
2006; Hannan et al. 2012; Hannan and Thakker 2013). NSHPT is characterized by severe neonatal 
hypercalcaemia (serum calcium concentrations are typically 3.5-5.0 mmol/L), 5-10 fold elevations of 
serum PTH concentrations, marked parathyroid gland enlargement, failure to thrive, and 
hyperparathyroid skeletal disease leading to multiple fractures and respiratory distress (Hannan and 
Thakker 2013; Murphy, et al. 2016). Parathyroidectomy is usually required to treat NSHPT, and 
bisphosphonates have been successfully used in some patients to manage marked hypercalcaemia and 
skeletal demineralization prior to parathyroid surgery (Waller, et al. 2004; Wilhelm-Bals, et al. 2012). 
Severe neonatal hypercalcaemia has also been reported in association with heterozygous loss-of-
function CaSR mutations, and these findings indicate that NSHPT may be due to factors other than 
mutant gene dosage, for example the degree of severity of a dominant-negative mutation, or maternal 
serum calcium concentration may play a role in the phenotypic expression of a CaSR mutation in the 
neonate (Hannan and Thakker 2013). More than 25 different CaSR mutations have been described in 
association with NSHPT, of which >40% are either nonsense or frameshift mutations that are 
predicted to lead to a truncated CaSR (Hannan et al. 2012; Hannan and Thakker 2013).  
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Primary hyperparathyroidism (PHPT) and marked hypercalcaemia presenting after infancy 
Loss-of-function CaSR mutations may occasionally present after the neonatal period with marked 
hypercalcaemia. Indeed, homozygous loss-of function mutations, which are located at the N-terminal 
region of the CaSR, have been reported to lead to symptomatic hypercalcaemia in childhood or early 
adulthood, which required treatment with parathyroidectomy (Chikatsu, et al. 1999; Miyashiro, et al. 
2004). Occasionally, heterozygous and homozygous loss-of function CaSR mutations have been 
detected in adult patients with PHPT caused by parathyroid adenomas or hyperplasia (Table 1) 
(Hannan, et al. 2010a). The occurrence of PHPT or severe FHH after infancy may be due to the 
degree of loss-of-function associated with the underlying CaSR mutations. Indeed, the homozygous 
CaSR mutations, present in these patients, have been associated with milder alterations in Ca2+i 
signalling than homozygous mutations leading to NSHPT (Hannan et al. 2010a). An analysis of CaSR 
mutations identified in patients with PHPT or severe FHH that presented after infancy, has indicated 
that CaSR mutations located in the receptor ECD are associated with more severe hypercalcaemia 
which is recalcitrant to treatment by parathyroidectomy, possibly due to multiple gland involvement 
(Hannan et al. 2010a). These findings may have some clinical utility in identifying those patients (i.e. 
with CaSR ECD mutations) in whom a full neck exploration is required, as they are more likely to 
have multi-gland disease (Hannan et al. 2010a; Hannan and Thakker 2013). 
 
 
Autosomal dominant hypocalcaemia type 1 (ADH1) and Bartter syndrome type V 
ADH is comprised of two genetically distinct disorders, designated as ADH types 1 and 2 (Table 1), 
which are caused by germline gain-of-function mutations of the CaSR and Gα11 proteins, respectively 
(Nesbit et al. 2013a; Pearce, et al. 1996b; Pollak, et al. 1994). ADH1 (OMIM #601198) accounts for 
~70% of all ADH cases (Nesbit et al. 2013a). ADH is characterized by mild to moderate 
hypocalcaemia, with serum calcium concentrations, adjusted for variations in serum albumin 
concentrations, rarely below 1.50 mmol/L, and ~50% of patients may develop hypocalcaemic 
symptoms such as paraesthesia, carpo-pedal spasms and seizures (Hannan and Thakker 2013; Nesbit 
et al. 2013a; Pearce et al. 1996b). Although ADH is associated with increased circulating phosphate 
concentrations and inappropriately low or normal PTH concentrations, this is considered to represent 
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a distinct disease entity from hypoparathyroidism, as affected individuals generally have PTH 
concentrations that are detectable and within the reference range, and also a relative hypercalciuria 
that is characterised by urinary calcium to creatinine ratios that are within or above the reference 
range (Hannan and Thakker 2013; Nesbit et al. 2013a; Pearce et al. 1996b). Ectopic calcification of 
the kidneys and basal ganglia is a common feature of ADH and affects >35% of patients (Hannan and 
Thakker 2013; Nesbit et al. 2013a; Pearce et al. 1996b). Patients with severe gain-of-function CaSR 
mutations may also have Bartter syndrome type 5, which is characterised by hypokalaemic alkalosis, 
renal salt wasting and hyperreninaemic hyperaldosteronism (Kinoshita, et al. 2014; Vargas-Poussou, 
et al. 2002; Watanabe, et al. 2002). Mutational analysis is commonly required for the diagnosis of 
ADH, and >70 different CaSR mutations have been identified to date in individuals affected with 
ADH1 (Hannan et al. 2012; Hannan and Thakker 2013). Of these mutations, 95% are heterozygous 
missense substitutions (Hannan and Thakker 2013), and structure-function analyses of these 
mutations have defined key peptide motifs of the CaSR that maintain this receptor in an inactive 
conformation. In particular, gain-of-function mutations cluster within the second peptide loop of the 
extracellular VFT domain (residues 116-136) (Fig. 3) (Jensen, et al. 2000) that contributes to the 
interface of the dimeric CaSR (Hu and Spiegel 2007; Zhang et al. 2016). Mutations affecting this 
extracellular peptide loop may lead to a gain-of-function by promoting conformational changes such 
as dimer rotation that facilitates receptor activation (Hu and Spiegel 2007). A second hotspot for 
ADH1-associated mutations is located in a region that encompasses transmembrane domains 6 and 7, 
and the intervening third extracellular loop of the CaSR (residues 819-837) (Fig. 3) (Hu, et al. 2005), 
and which is likely important for locking the ligand-unbound family C GPCRs in an inactive 
conformation by forming a network of interactions with other transmembrane domains (Dore, et al. 
2014) that inhibits the binding of G-proteins. Cellular studies have demonstrated the majority of 
ADH1-causing CaSR mutations to cause a signalling bias by coupling more strongly to Ca2+i 
mobilisation than to the MAPK pathway, which contrasts with FHH1-causing CaSR mutations, which 
are biased towards MAPK signalling (Leach et al. 2012). 
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Use of calcimimetic and calcilytic drugs for disorders caused by CaSR mutations  
Calcimimetics are ligands that mimic or enhance the effects of Ca2+o at the CaSR, and are divided into 
two types: type I calcimimetics are agonists, which include naturally occurring ligands such as 
polyvalent cations; and type II calcimimetics are positive allosteric modulators that include L-amino 
acids and cinacalcet, which is a synthetic amino alcohol compound (Nemeth, et al. 2004). Calcilytics 
are inhibitors of CaSR function, and to-date no endogenous calcilytic compounds have been 
identified. However, synthetic calcilytic compounds have been generated, and shown to act as 
negative allosteric modulators of the CaSR (Nemeth and Shoback 2013). A recent study has identified 
a putative binding cavity for synthetic calcimimetic and calcilytic compounds within the extracellular 
portion of the CaSR TMD and delineated key glutamate residues within the binding cavity, which 
may facilitate the conformational changes that lead to altered receptor activity upon the binding of 
these compounds (Leach, et al. 2016). Calcimimetic drugs represent a potential targeted therapy for 
NSHPT and symptomatic forms of FHH1, and have been shown to improve the signalling by loss-of-
function CaSR mutants in vitro (Leach, et al. 2013; Rus, et al. 2008), and to also act as 
pharmacochaperones that facilitate correct protein folding and plasma membrane targeting of mutant 
CaSRs (Huang and Breitwieser 2007; White et al. 2009). These in vitro effects of calcimimetic drugs 
are in keeping with reports of FHH1 patients with marked hypercalcaemia or complications such as 
recurrent pancreatitis who have responded to treatment with cinacalcet, which is licensed for the 
management of certain hyperparathyroid disorders (Festen-Spanjer, et al. 2008; Timmers, et al. 2006). 
Cinacalcet has also been successfully used to manage life-threatening hypercalcaemia in NSHPT 
probands harbouring a heterozygous CaSR mutation, Arg185Gln (Gannon, et al. 2014), but to be 
ineffective for NSHPT caused by biallelic deletional CaSR mutations (Atay, et al. 2014). 
Symptomatic ADH is conventionally treated with calcium and active vitamin D preparations, 
however these therapies do not rectify the underlying pathophysiological alterations in parathyroid 
and renal tubular function, and their use predisposes affected individuals to the development of 
marked hypercalciuria, nephrocalcinosis, nephrolithiasis and renal impairment (Hannan and Thakker 
2013; Nesbit et al. 2013a; Pearce et al. 1996b). ADH1 patients have also been treated with 
recombinant PTH (1-34) (teriparatide), however when administered by once or twice daily bolus 
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injections, this peptide may not always prevent hypercalciuric renal complications (Theman, et al. 
2009). Calcilytic drugs, which are CaSR negative allosteric modulators, represent a potential targeted 
therapy for ADH1. Calcilytics comprise two main classes of compounds, which are the amino 
alcohols (e.g. NPS-2143, ronacalceret and JTT-305/MK-5442) and quinazolinones (e.g. ATF936 and 
AXT914) (Nemeth and Goodman 2016). In vitro studies have shown NPS-2143, which is a long 
acting calcilytic, to correct the gain-of-function associated with ADH-causing CaSR mutations 
(Hannan, et al. 2015b; Hu et al. 2005; Letz, et al. 2010; Lia-Baldini, et al. 2013). However, the in 
vitro efficacy of NPS-2143 was reduced by mutations affecting NPS-2143-binding residues within the 
TMD (Hu et al. 2005; Letz et al. 2010). In contrast, the quinazolinone calcilytic drugs (ATF936 and 
AXT914) have been demonstrated to rectify the excessive signaling responses of all ADH mutants 
evaluated to date, including those mutations leading to constitutive activation and/or Bartter syndrome 
type 5 (Letz, et al. 2014). To assess whether calcilytics may ameliorate the hypocalcaemia associated 
with ADH1, these drugs have been administered to mouse models harbouring germline gain-of-
function CaSR mutations. In a single-dose in vivo study, NPS-2143 was administered to Nuf mice, 
which have hypocalcaemia, reduced plasma PTH concentrations and ectopic calcification in 
association with a germline gain-of-function Casr mutation, Leu723Gln (Hannan et al. 2015b; Hough, 
et al. 2004). Intraperitoneal injection of NPS-2143 significantly increased plasma calcium and PTH 
concentrations in heterozygous- and homozygous-affected Nuf mice at 1-hour after administration, 
with values returning to baseline after 4-hours, and the elevations in plasma calcium induced by NPS-
2143 were not associated with any increase in urinary calcium excretion (Hannan et al. 2015b). 
Longer-term in vivo studies involving the JTT-305/MK-5442 calcilytic compound have been 
undertaken in two ADH1 mouse models, which harbor germline Cys129Ser and Ala843Glu gain-of-
function CaSR mutations, respectively (Dong, et al. 2015). Administration of JTT-305/MK-5442 by 
daily oral gavage over a 12-week period led to sustained increases in serum calcium concentrations 
and a significant reduction in urinary calcium excretion in both ADH1 mouse mutants (Dong et al. 
2015). Recently, a calcilytic compound known as NPSP795 has been evaluated in a clinical trial 
involving five ADH1 patients, and intravenous administration of NPSP795 significantly increased 
plasma PTH concentrations and reduced urinary calcium excretion (Ramnitz, et al. 2015). However, 
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circulating calcium levels were not altered in this study, and the optimal dosing regimen for 
NPSP795, which is a short-acting calcilytic compound intended to elicit a rapid and transient increase 
in plasma levels of PTH, remains to be established in ADH1 patients (Ramnitz et al. 2015).  
 
Disorders associated with G-protein-α11 subunit mutations 
 
Germline mutations affecting Gα11, which is encoded by the GNA11 gene (Fig. 4) on chromosome 
19p13.3, have recently been identified as the genetic cause of FHH and ADH in some patients, and 
this finding has revealed Gα11 to be a major component of the CaSR signalling pathway, and 
highlighted its importance in Ca
2+
o homeostasis. Loss-of-function Gα11 mutations give rise to FHH2 
(Gorvin, et al. 2016; Nesbit et al. 2013a), whilst germline gain-of-function Gα11 mutations are 
associated with ADH2 (Table 1, Fig. 4) (Li, et al. 2014; Mannstadt, et al. 2013; Nesbit et al. 2013a; 
Piret, et al. 2016) and somatic gain-of-function Gα11 mutations cause uveal melanomas (Van 
Raamsdonk, et al. 2010). 
 
Familial hypocalciuric hypercalcaemia type 2 (FHH2) 
The existence of a genetically distinct form of FHH was first highlighted by genetic linkage studies 
that mapped an FHH locus to chromosome 19p, which contains the GNA11 locus, and this form of 
FHH was designated as FHH2 (OMIM #145981) (Table 1) (Heath, et al. 1993). GNA11 was 
considered a likely candidate gene for FHH2, as this encodes the Gα11 protein, which is highly 
expressed in the parathyroid glands (Varrault et al. 1995) and represents a signalling partner for the 
CaSR (Hofer and Brown 2003). Indeed, mouse model studies have demonstrated parathyroid specific 
ablation of Gα11, and the related Gαq protein, to result in marked hypercalcaemia, hyperparathyroidism 
and parathyroid gland enlargement (Wettschureck et al. 2007). DNA sequence analysis of the 
reported FHH2 kindred revealed a germline heterozygous GNA11 mutation that resulted in an in-
frame isoleucine deletion at codon 199 or 200 (Ile199/200del) of the Gα11 protein (Nesbit et al. 
2013a). Mutational analysis of the GNA11 gene in additional FHH probands, who did not harbour 
CASR mutations, has identified heterozygous Leu135Gln and Thr54Met missense mutations in two 
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unrelated probands (Gorvin et al. 2016; Nesbit et al. 2013a). The Thr54Met, Leu135Gln and 
Ile199/200del Gα11 mutations are all associated with a mild FHH phenotype characterised by serum 
adjusted-calcium concentrations <2.80 mmol/L (Gorvin et al. 2016; Nesbit et al. 2013a). In keeping 
with these clinical findings, in vitro studies that have shown these FHH2-associated Gα11 mutations to 
lead to a mild impairment of CaSR signal transduction (Gorvin et al. 2016; Nesbit et al. 2013a). 
Indeed, the Thr54Met, Leu135Gln and Ile199/200del FHH2 mutants were associated with around a 
30% increase in the half-maximal effective concentration (EC50) of CaSR-expressing cells, whereas 
CaSR mutations leading to FHH1 generally cause a >50% increase in the EC50 value (Bai, et al. 1996; 
Hannan et al. 2012; Pearce, et al. 1996a). 
Homology modelling revealed the FHH2-causing mutations to be located within key regions 
of the Gα11-subunit, which consists of a GTPase domain that binds GDP and GTP, and a smaller 
helical domain that acts as a clasp to secure these bound guanine-nucleotides (Fig. 4) (Oldham and 
Hamm 2008). Thus, the Ile199/200del mutation is located within the GTPase domain and predicted to 
disrupt a hairpin loop, which comprises part of the Gα-GPCR interface and is also situated between 
flexible “switch” regions (Fig. 4) that undergo substantial conformational changes upon GTP binding 
(Nesbit et al. 2013a). In contrast, the Leu135Gln mutation is located in the Gα11 helical domain (Fig. 
4) (Nesbit et al. 2013a), and not predicted to influence CaSR-Gα11 coupling, but instead likely 
diminishes CaSR signal transduction by influencing the interaction of Gα11 with downstream 
effectors. The Thr54Met mutation is located at the interface between GTPase and helical domains 
(Fig. 4), and predicted to impair coupling and/or dissociation of Gα11 from the CaSR by influencing 
guanine-nucleotide binding at the interdomain interface (Gorvin et al. 2016). Thus, the identification 
of these FHH2-causing Gα11 mutations has revealed residues critical for Gα11-subunit function. 
 
Autosomal dominant hypocalcaemia type 2 (ADH2) 
Following the identification of loss-of-function Gα11 mutations leading to FHH2, it was hypothesised 
that gain of-function germline Gα11 mutations may have opposite effects on Ca
2+
o homeostasis, and 
give rise to a disorder with an ADH-like phenotype. DNA sequence analysis of eight ADH probands, 
who did not harbour CaSR mutations, identified germline heterozygous Gα11 mutations in two 
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individuals (Nesbit et al. 2013a). In vitro functional studies of these mutations, which comprised 
Arg181Gln and Phe341Leu Gα11 missense substitutions, demonstrated cells expressing the mutant 
Gα11 proteins to have enhanced sensitivity to Ca
2+
o, consistent with a gain-of-function (Nesbit et al. 
2013a). In parallel with these studies, genetic linkage studies of two unrelated hypocalcaemic 
kindreds mapped the disease locus to chromosome 19p13.3, which is the location of the GNA11 locus, 
and DNA sequence analysis revealed the occurrence of germline heterozygous Gα11 mutations, 
Arg60Cys and Ser211Trp (Mannstadt et al. 2013). Moreover, heterozygous Arg60Leu and 
Val340Met Gα11 mutations have been identified by whole-exome sequencing in additional ADH 
kindreds, and these mutations were demonstrated to lead to enhanced CaSR-mediated signal 
transduction (Li et al. 2014; Piret et al. 2016). These individuals and families with gain-of-function 
Gα11 mutations, who were designated as having ADH2 (OMIM #615361) (Table 1), generally had 
serum adjusted-calcium concentrations ranging from 1.75-2.15 mmol/L, and affected individuals 
typically presented with hypocalcaemic symptoms such as paraesthesia, muscle cramps, carpo-pedal 
spasm and seizures (Li et al. 2014; Mannstadt et al. 2013; Nesbit et al. 2013a; Piret et al. 2016). Some 
ADH2 patients were susceptible to treatment-related hypercalciuria, nephrocalcinosis and 
nephrolithiasis (Li et al. 2014; Piret et al. 2016), although affected individuals generally had a milder 
urinary phenotype, with significantly reduced urinary calcium excretion when compared to ADH1 
patients who harbor gain-of-function CaSR mutations (Li et al. 2014). Furthermore, patients with 
germline gain-of-function Gα11 mutations, in contrast to patients with gain-of-function CaSR 
mutations, may harbour non-calcitropic phenotypes. For example, studies of the kindred with the 
Arg60Leu Gα11 mutation showed this to be associated with impaired postnatal growth, and affected 
adults were significantly shorter than unaffected adult family members (height >2SD below mean of 
unaffected individuals) (Li et al. 2014). In addition, some affected members of the kindred with the 
Val340Met Gα11 mutation were found to have keratoconus, a corneal disorder (Piret et al. 2016). 
In contrast to germline gain-of-function Gα11 mutations, which affect Ca
2+
o homeostasis, 
somatic gain-of-function Gα11 mutations have been reported to cause uveal melanoma, a primary 
intraocular tumor, by inducing constitutive up-regulation of proliferative signalling involving 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) (Van Raamsdonk et al. 2010), which are 
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components of the MAPK signaling pathway. However, in vitro studies have shown that the ADH-
causing Gα11 mutations do not have such oncogenic potential, and that these ADH-causing germline 
mutants phosphorylated ERK1/2 only in the presence of Ca
2+
o, and were thus not constitutively 
activating (Babinsky, et al. 2016). Thus, the milder disturbance of signalling associated with the 
ADH2 mutants may provide an explanation for their occurrence as a post-natal phenotype that can be 
transmitted as an autosomal dominant disorder, in contrast to the uveal melanoma-associated 
constitutively activating G-protein mutation, Gln209Leu, which has been shown to be cytotoxic when 
expressed at high levels (Radhika and Dhanasekaran 2001), and is likely to be embryonically lethal if 
present within the germline. 
  An analysis of the location of ADH2-causing mutations revealed the mutated Arg60 and 
Arg181 residues to be situated adjacent to the linker 1 and linker 2 peptides, respectively (Mannstadt 
et al. 2013; Nesbit et al. 2013a), which are predicted to act as a hinge that connects the Gα11 GTPase 
domain with the helical domain, thereby allowing these two domains to form a clamshell around 
bound guanine nucleotides (Fig. 4). Thus, mutations affecting the Arg60 and Arg181 residues may 
lead to the opening of the Gα11 clamshell and induce G-protein activation by promoting exchange of 
GDP for GTP. The ADH2-causing Ser211Trp mutation is located within the region of Gα11, which 
binds to the Gβγ heterodimer, and this mutation may promote the dissociation of the Gα11 subunit, 
thus enhancing CaSR-mediated signal transduction (Mannstadt et al. 2013). The mutated Phe341 
residue is located at the Gα-subunit C-terminus (Fig. 4) and forms part of a cluster of phenylalanine 
residues that likely stabilises GTP in a conformation required for its hydrolysis (Kaya, et al. 2014; 
Sun, et al. 2015), and the ADH2-causing Phe341Leu mutation is thus predicted to activate Gα11 by 
impairing the hydrolysis of GTP to GDP. In contrast to these predicted effects of the Phe341Leu 
mutation, the neighboring Val340 residue is not involved in GDP/GTP exchange (Rasmussen, et al. 
2011; Sun et al. 2015), but instead may influence the stability of Gα-GPCR interactions (Piret et al. 
2016). 
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Use of calcimimetic and calcilytic drugs for disorders caused by Gα11 mutations 
Although calcimimetic and calcilytic compounds represented targeted therapies for patients with 
CaSR mutations resulting in symptomatic forms of FHH1 and ADH1, it was unclear if these CaSR 
allosteric modulators may rectify abnormalities of the downstream Gα11 protein, and thus have 
potential benefit for FHH2 and ADH2 patients. Recent in vitro studies have revealed cinacalcet and 
NPS-2143 to correct the loss- and gain-of-function associated with Gα11 mutations leading to FHH2 
and ADH2, respectively (Babinsky et al. 2016). Indeed, siRNA knockdown studies showed these 
CaSR allosteric modulators to directly influence signaling mediated by the FHH2 and ADH2 mutant 
Gα11 proteins rather than by exerting indirect effects on endogenously expressed wild-type Gα11 
proteins (Babinsky et al. 2016). However, some Gα11 mutations (Ile199/200del and Phe341Leu) 
showed diminished sensitivity to cinacalcet and NPS-2143 (Babinsky et al. 2016) and these 
differences in the sensitivities of the mutants to CaSR-targeted drugs may be explained by an analysis 
of the crystal structure of the G-protein alpha-s (Gαs) complexed with the β2-adrenergic receptor 
(Rasmussen et al. 2011), which showed residues homologous to Ile199 and Phe341, in the related Gαs 
protein to be located within a hydrophobic pocket at the interface between GPCR and Gα-subunit 
(Fig. 5). Thus, Gα11 mutations located at the GPCR-Gα interface may potentially influence the 
efficacy of CaSR allosteric modulators (Babinsky et al. 2016). The NPS-2143 calcilytic compound 
was also shown to rectify the constitutive activation caused by a uveal melanoma associated Gα11 
mutation, and these findings suggest a potential therapeutic role for calcilytics in the management of 
this intraocular tumour (Babinsky et al. 2016). 
 
Disorders associated with adaptor-related protein complex 2 sigma subunit mutations 
 
Familial hypocalciuric hypercalcaemia type 3 (FHH3) 
Genetic linkage studies of two multi-generational FHH unrelated kindreds from Oklahoma and 
Northern Ireland, designated FHHOK and FHHNI, respectively (Hannan, et al. 2010b; Lloyd, et al. 
1999; McMurtry, et al. 1992; Nesbit, et al. 2010), mapped the disease locus, designated FHH3, to 
chromosomal 19q13.3, thereby highlighting a third genetically distinct form of FHH (FHH3, OMIM 
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#600740) (Table 1). FHH3 was associated with elevations in plasma PTH, mild hypophosphataemia 
and osteomalacia in affected family members above the age of 30 years (McMurtry et al. 1992; Nesbit 
et al. 2010). Whole exome capture and high-throughput sequence analysis revealed affected 
individuals from the unrelated FHHOK and FHHNI kindreds to harbour the same heterozygous 
germline Arg15Cys mutation of the adaptor-related protein complex 2 sigma subunit 1  (AP2S1) gene, 
which encodes the σ-subunit of the ubiquitously expressed heterotetrameric AP2 complex (Nesbit et 
al. 2013b). The AP2 complex is a central component of clathrin-coated vesicles, and facilitates the 
endocytosis of plasma membrane proteins such as GPCRs (Kim and Benovic 2002). To date, AP2S1 
mutations have been reported in >60 FHH3 patients and families, and affected individuals all harbour 
a heterozygous missense mutation affecting the Arg15 residue of the encoded AP2σ subunit (Fig. 6) 
and resulting in Arg15Cys, Arg15His or Arg15Leu (Fujisawa, et al. 2013; Hannan, et al. 2015a; 
Hendy, et al. 2014; Nesbit et al. 2013b; Vargas-Poussou, et al. 2016). Crystallography studies have 
revealed the Arg15 residue to play a key role in binding to membrane cargo proteins (Fig. 6) (Kelly, 
et al. 2008), and it is predicted that these FHH3-causing Arg15 mutations disrupt an interaction 
between the AP2 complex and the intracellular carboxyl terminus of the CaSR, thereby impairing 
endocytosis of this GPCR (Nesbit et al. 2013b). This hypothesis is supported by in vitro expression 
studies that have demonstrated these FHH3-causing AP2σ mutations to alter CaSR cell-surface 
expression and impair signal transduction in a dominant-negative manner (Hannan et al. 2015a; 
Nesbit et al. 2013b). Thus, these studies have revealed a role for the AP2 endocytic complex in the 
regulation of Ca
2+
o homeostasis.  
Nucleotide substitutions affecting codon 15 of the AP2S1 gene are predicted to result in the 
replacement of the wild-type Arg residue with either a mutant Cys, Gly, His, Leu, Pro or Ser residue, 
and all of these potential missense AP2σ substitutions have been demonstrated to diminish CaSR 
signal transduction in vitro (Hannan et al. 2015a). However, to date only Arg15Cys, Arg15His and 
Arg15Leu AP2σ mutations have been observed in FHH3 patients (Fig. 6) (Fujisawa et al. 2013; 
Hannan et al. 2015a; Hendy et al. 2014; Nesbit et al. 2013b; Vargas-Poussou et al. 2016), and the 
likely cause of this mutation bias has been revealed by cellular studies. These studies have shown that 
the non-observed Arg15Gly, Arg15Pro and Arg15Ser AP2σ mutants impair cell growth in vitro 
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(Hannan et al. 2015a), and thus, a possible explanation for the absence of the Arg15Gly, Arg15Pro 
and Arg15Ser AP2σ mutations in patients, is that these deleterious mutations are embryonically 
lethal, whereas the FHH3-causing AP2σ mutations (Arg15Cys, Arg15His and Arg15Leu) are 
tolerated and compatible with embryonic and post-natal survival (Hannan et al. 2015a).  
FHH3 may be associated with symptomatic hypercalcaemia and reduced bone mineral 
density, and with cognitive deficits and/or behavioural disturbances in children harbouring the 
Arg15Cys or Arg15Leu AP2σ mutations (Hannan et al. 2015a). Moreover, FHH3 is associated with a 
more severe biochemical phenotype than FHH1, which is characterized by significantly higher serum 
calcium and magnesium concentrations and a significantly reduced fractional excretion of calcium 
(Hannan et al. 2015a; Vargas-Poussou et al. 2016). Furthermore, an analysis of adults and children 
with AP2σ mutations, by one study, has revealed a genotype-phenotype correlation with Arg15Leu 
probands having significantly higher serum calcium concentrations and presenting at a younger age, 
typically in childhood, compared to probands with Arg15Cys or Arg15His mutations (Hannan et al. 
2015a); the absence of such a genotype-phenotype correlation in another study (Vargas-Poussou et al. 
2016), which consisted of mainly adult FHH3 patients, suggests that the more severe hypercalcaemia 
associated with the Arg15Leu mutation may possible be age-dependent.  
 
Use of cinacalcet for symptomatic hypercalcaemia caused by AP2σ mutations 
Cinacalcet has been evaluated as a therapy for symptomatic hypercalcaemia associated with FHH3. In 
vitro studies revealed this calcimimetic drug to rectify the significantly impaired intracellular calcium 
and MAPK responses associated with all three FHH3-causing AP2σ mutations (Howles, et al. 2016), 
and the administration of cinacalcet at a dose of 30-60mg daily to three symptomatic FHH3 probands, 
each harboring an Arg15Cys, Arg15His or Arg15Leu AP2σ mutation, led to >20% reductions in 
serum calcium concentrations and improved symptoms in all three FHH probands (Howles et al. 
2016). These studies show that cinacalcet-mediated allosteric modulation of the CaSR can rectify the 
loss-of-function and symptomatic hypercalcaemia that are associated with the three types of FHH3-
causing Arg15 AP2σ mutations. Cinacalcet has also been shown to correct the hypercalcaemia in a 
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patient with chromosome 22q11.2 deletion syndrome who also had an Arg15Leu AP2σ mutation 
(Tenhola, et al. 2015). 
 
Autosomal dominant hypocalcaemia type 3: The search for AP2σ mutations 
Germline coding-region mutations of the CASR and GNA11 genes, which enhance CaSR-mediated 
signal transduction, have been identified in around 70% of ADH cases (Hannan et al. 2012; Nesbit et 
al. 2013a). This raises the possibility that ADH patients who do not harbour such mutations may 
instead have abnormalities of the untranslated or non-coding regulatory regions of CASR and GNA11, 
or have mutations involving other mediators of Ca
2+
o homeostasis. Indeed, it had been postulated that 
some patients with ADH might harbour AP2σ mutations which enhance the sensitivity of CaSR-
expressing cells to Ca
2+
o, and this putative form of ADH was designated ADH type 3 (ADH3) 
(Rogers, et al. 2014). However, an analysis of the AP2S1 gene in 19 patients and families who were 
considered to have ADH but did not have mutations of CASR and GNA11, or of other genes 
associated with isolated hypoparathyroidism, such as PTH or GCMB, failed to identify coding-region 
mutations or copy number variants (CNVs) (Rogers et al. 2014). Moreover, investigations of 10 
familial cases and 50 sporadic cases of isolated hypoparathyroidism for coding-region mutations or 
CNVs affecting AP2S1 did not identify any abnormalities (Lambert, et al. 2014). Thus, these studies 
indicated that AP2σ mutations are unlikely to cause hypocalcaemic disorders such as ADH. 
 
 
Conclusion 
 
The identification and characterization of gene abnormalities underlying FHH and ADH has led to the 
delineation of a parathyroid and renal G-protein-coupled Ca2+o-sensing mechanism, which involves 
the CaSR, Gα11 and AP2σ proteins. The CaSR has been shown to play a pivotal role in the regulation 
of Ca2+o concentrations, whilst the Gα11 protein appears to be a key mediator of downstream CaSR 
signal transduction, and the AP2σ protein is likely required for both CaSR signaling and trafficking. 
These studies have also provided new insights into the clinical phenotypes of Ca
2+
o-sensing disorders 
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and revealed FHH3 to represent a distinct disorder of Ca2+o homeostasis, which is characterized by 
symptomatic hypercalcaemia, low BMD and cognitive deficits. Moreover, advances in the treatment 
of FHH and ADH have been made, and calcimimetic and calcilytic drugs have been shown to be of 
potential benefit for managing symptomatic forms of these Ca2+o-sensing disorders.  
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Figure legends 
 
Figure 1 Overview of Ca
2+
o homeostasis. The parathyroid CaSR senses reductions in Ca
2+
o, which 
leads to a rapid rise in PTH secretion. The increased circulating PTH acts via the PTH1-receptor 
(PTH1R) in the kidneys and bone. The skeletal effects of PTH are to increase bone resorption, thereby 
releasing calcium into the extracellular fluid. In the kidney, PTH increases calcium reabsorption and 
stimulates the proximal renal tubular 1-α-hydroxylase (1αOHase) enzyme, which promotes the 
synthesis of the active 1,25-dihydroxyvitamin D3 (1,25D3) metabolite from 25-hydroxyvitamin D3 
(25D3), which is the major circulating form of vitamin D. The elevated 1,25D3 acts on the intestine 
via the vitamin D receptor (VDR) to increase absorption of dietary calcium. Thus, in response to 
hypocalcaemia, the secretion of PTH, by these direct and indirect actions leads to the restoration of 
normocalcaemia. Moreover, the kidney CaSR senses reductions in Ca
2+
o, and promotes urinary 
calcium reabsorption independently of the actions of PTH. The rise in Ca2+o and 1,25D3 
concentrations mediated by PTH act on the parathyroid glands to induce feedback inhibition of further 
PTH secretion.  
 
Figure 2 Role of the CaSR, Gα11 and AP2 complex in the regulation of PTH secretion and renal 
tubular calcium reabsorption. The binding of calcium (red filled-in circle, Ca2+) to the extracellular 
bilobed venus fly trap (VFT) domain of the CaSR (grey) results in Gα11 (yellow) dependent 
stimulation of phospholipase C-beta (PLCβ) (dark blue) activity, which catalyses the formation of 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-
bisphosphate (PIP2). An accumulation of IP3 mediates the rapid release of calcium into the cytosol 
from intracellular stores, whilst DAG activates the MAPK cascade. These intracellular signalling 
events lead to a decrease in PTH secretion from the parathyroid chief cell and reduction in renal 
tubular calcium reabsorption. CaSR cell-surface expression is regulated by agonist-driven insertional 
signaling (ADIS) (not shown) (Grant et al. 2011) and also by an endocytic complex comprising 
clathrin, β-arrestin (green) and the AP2 complex (orange), which traffic this GPCR to the endosomal-
lysosomal degradation pathway (light blue) or recycle the CaSR back to the cell-surface (Breitwieser 
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2013). Loss- and gain-of function mutations of the CaSR lead to FHH1 and ADH1, respectively. 
Whilst, loss- and gain-of function mutations of the Gα11 subunit are associated with FHH2 and ADH2, 
respectively, and loss-of-function mutations of the AP2σ subunit lead to FHH3. 
 
Figure 3 (a) Schematic representation of the genomic organisation of the CASR gene showing 
mutational hotspots for disease-associated missense mutations. The CASR gene consists of six coding 
exons (2-7), and the start (ATG) and stop (TGA) codons are in exons 2 and 7, respectively. The 5’ 
portion of exon 2, and the 3’ portion of exon 7 are untranslated (open boxes). The 3’ portion of exon 
2, exons 3, 4, 5, 6 and the 5’ portion of exon 7, encode the extracellular domain (light grey), and the 
mid portion of exon 7 encodes the transmembrane (dark grey) and intracellular (black) domains. More 
than 170 different missense CASR mutations have been reported in patients with FHH1, NSHPT, 
adult-onset PHPT, ADH1 and Bartter syndrome type V (Hannan and Thakker 2013). These mutations 
affect >110 different codons scattered throughout the CASR gene. Twenty-eight codons (>20% of all 
mutated codons) represent mutational hotspots as they are the site of recurrent missense mutations 
(solid lines) that have been reported in three or more probands (mutational frequency of >1.5%), 
and/or affected by multiple (3 or more) different missense mutations (dashed lines). Mutations 
affecting these codons are clustered in three regions, which are the 2
nd
 peptide loop of the 
extracellular domain, venus flytrap (VFT) cleft region Ca2+o binding site, and the region 
encompassing transmembrane domains (TMD) 6 and 7. Codons 173, 221, 297 and 802 (thickened 
lines) are the site of missense mutations that may lead to a loss- or gain-of-function, and are termed 
“switch” codons or residues. (b) Homology modelling of the CaSR VFT cleft region ligand-bound 
Ca2+o binding site based on the crystal structure of the metabotropic glutamate receptor type 1. The 
Leu173 (L173) and Pro221 (P221) switch residues are predicted to be located in short α-helices 
within lobes 1 and 2, respectively, that form the entrance to the Ca2+o binding site within the VFT 
cleft. The L173 and P221 side chains are shown in purple, the side chains of predicted Ca2+o binding 
residues (Ser147 (S147), Ser170 (S170), Asp190 (D190), Tyr218 (Y218) and Glu297 (E297)) are 
shown in cyan, and a bound calcium ion is shown as a green sphere. The side chains of L173 and 
P221 are predicted to extend across the entrance to the Ca
2+
o binding site and mutations affecting 
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these residues may lead to opposing effects on CaSR function by influencing the entry and binding of 
calcium within the VFT cleft region. Adapted from Hannan FM et al. Hum Mol Genet. 2012 21:2768-
78. 
 
Figure 4 (a) Schematic representation of the genomic organisation of the GNA11 gene showing 
germline disease-associated mutations. The GNA11 gene consists of 7 coding exons (1-7), and the 
start (ATG) and stop (TGA) codon are in exons 1 and 7, respectively. The 5’ portion of exon 1 and 
the 3’ portion of exon 7 are untranslated (open boxes). The 3’ portion of exon 2, exon 3 and 5’ portion 
of exon 4 encode the Gα11 helical domain, which is connected by two short peptides, termed linker 1 
(L1) and linker 2 (L2), to the GTPase domain. The Gα11 GTPase domain is encoded by the 3’ portion 
of exon 1, 5’ portion of exon 2, 3’ portion of exon 4 and exons 5-7. Three flexible regions, termed 
switch regions 1-3 (S1-S3, shown in blue), which undergo conformational changes during Gα11 
activation are encoded by exons 4 and 5. The location of reported FHH2- and ADH2-causing 
mutations are shown. (b) Three dimensional homology model of Gα11 showing the location of 
residues mutated in FHH2 (blue) and ADH2 (red). The homology model is based on the crystal 
structure of Gαq (PDB accession number 3AH8) (Nishimura, et al. 2010), which shares 90% amino 
acid identity with Gα11. The Gα11 helical and GTPase domains are shown bound to GDP aluminium 
fluoride (GDP-AlF4, green), which is a non-hydrolysable analogue of GTP. The three flexible switch 
regions are highlighted in cyan, and the L1 and L2 peptides are shown in yellow. The β2-β3 hairpin 
loop, which comprises part of the Gα-GPCR interface, is shown in orange. Adapted from Nesbit MA 
et al. NEJM. 2013 368:2476-86. 
 
 
Figure 5 Three-dimensional model of Gαs (brown) bound to the β2-adrenergic receptor (β2AR, 
green) showing location of residues homologous to the Gα11 Ile199 and Phe341 residues, which are 
mutated in FHH2 and ADH2, respectively. Gαs residues homologous to the Gα11 Ile199 and Phe341 
residues (red) are located within a hydrophobic region at the GPCR-Gα interface (black open circle). 
The β2AR-Gαs interface is formed by residues located within the β1 strand, hairpin loop linking the 
β2 and β3 strands, and the α5 helix of the Gαs protein, which interact with intracellular loop 2 (IL2) 
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of the β2AR. The Gαs Val217 (V217) and Phe376 (F376) residues, which are homologous to the Gα11 
Ile199 and Phe341 residues, comprise part of a hydrophobic pocket (curved line) at the Gα subunit 
surface, which facilitates the docking of the β2AR IL2 with the Gαs protein (Rasmussen et al. 2011).  
 
 
Figure 6 (a) Schematic representation of the genomic organisation of the AP2S1 gene showing the 
location of FHH3-causing mutations. The AP2S1 gene consists of 5 coding exons (1-5), and the start 
(ATG) and stop (TGA) codon are in exons 1 and 5, respectively. The 5’ portion of exon 1 and the 3’ 
portion of exon 5 are untranslated (open boxes). The AP2σ protein is encoded by the 3’ portion of 
exon 1, exons 2, 3, 4, and the 5’ portion of exon 5 (dark grey). The FHH3-causing mutations all affect 
the Arg15 residue and comprise Arg15Cys (R15C), Arg15His (R15H) and Arg15Leu (R15L) 
missense substitutions. (b) Three-dimensional model of the heterotetrameric AP2 complex, which is 
comprised of α- (purple), β- (yellow), µ- (light blue) and σ- (light brown) subunits (PDB accession 
number 2JKR, (Kelly et al. 2008)). The AP2 complex is bound to a cargo protein recognition motif 
(green) via key polar contacts (shown in the red dashed circle) involving the AP2σ Arg15 (R15) 
residue (dark blue) and Arg21 (R21) residue of the AP2α subunit. Adapted from Nesbit MA et al. Nat 
Genet. 2013 45:93-97. 
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Table 1. Familial disorders of Ca2+o sensing. 
 
Disorder OMIM  Inheritance Gene  Chromosomal 
localisation 
Clinical features 
Hypercalcaemic disorders      
Familial hypocalciuric hypercalcaemia type 1 (FHH1) 145980 Autosomal dominant CASR 3q21.1 Asymptomatic 
 
Familial hypocalciuric hypercalcaemia type 2 (FHH2) 145981 Autosomal dominant GNA11 19p13.3 Asymptomatic 
 
Familial hypocalciuric hypercalcaemia type 3 (FHH3) 600740 Autosomal dominant AP2S1 19q13.3 Hypercalcaemic symptoms in >20% of cases  
Low bone mineral density in >50% of cases 
Childhood cognitive deficits in >75% of cases 
 
Neonatal severe hyperparathyroidism (NSHPT) 239200 Autosomal recessive  
or dominant 
CASR 3q21.1 Hyperparathyroid bone disease 
Hypercalcaemic symptoms  
 
Adult-onset primary hyperparathyroidism (PHPT) - Autosomal recessive 
or dominant 
CASR 3q21.1 Nephrolithiasis in >40% of cases 
Low bone mineral density in >25% of cases 
 
Hypocalcaemic disorders      
Autosomal dominant hypocalcaemia type 1 (ADH1) 601198 Autosomal dominant CASR 3q21.1 Hypocalcaemic symptoms in ~50% of cases  
Ectopic calcifications in ~35% of cases 
 
Autosomal dominant hypocalcaemia type 2 (ADH2) 615361 Autosomal dominant GNA11 19p13.3 Hypocalcaemic symptoms in >75% of cases 
Short stature reported in a single kindred 
 
Bartter syndrome type V 601198 Autosomal dominant CASR 3q21.1 Renal salt wasting and hypokalaemia 
Hypocalcaemic symptoms in >75% of cases 
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